Abstract
Although there have been meaningful advances in our understanding of the symptoms and underlying pathogenesis of Alzheimer disease (AD), we still cannot predict which individuals with mild cognitive impairment (MCI) will worsen or develop AD. There is a pressing need for identification of optimal clinical biomarkers to predict progression and conversion to dementia in patients with MCI. This important issue is tackled in the current issue of Neurology ®. Landau et al.1 compared genetic ( APOE e4 allele frequency), biochemical (CSF Aβ1–42, t-tau, p-tau181p), functional and structural neuroimaging (FDG-PET, hippocampal volume), and cognitive (episodic memory performance) biomarkers in a large group of patients with MCI to determine which combination had the best predictive value for progression or conversion to AD. Their major finding was that patients with amnestic MCI with abnormal FDG-PET and low episodic memory performances were almost 12 times more likely to convert to AD than individuals who were normal on both measures. CSF markers and, marginally, FDG-PET abnormalities were predictors of cognitive decline. Landau et al. concluded that …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
